Zacks: Analysts Set $12.00 Target Price for Athersys, Inc. (ATHX)

Shares of Athersys, Inc. (NASDAQ:ATHX) have received a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus target price of $12.00 for the company and are forecasting that the company will post ($0.08) EPS for the current quarter, according to Zacks. Zacks has also assigned Athersys an industry rank of 113 out of 265 based on the ratings given to its competitors.

ATHX has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Athersys from a “buy” rating to a “hold” rating in a report on Thursday, August 31st. Maxim Group set a $12.00 price target on Athersys and gave the stock a “buy” rating in a report on Monday, August 7th. Finally, ValuEngine raised Athersys from a “sell” rating to a “hold” rating in a report on Friday, September 15th.

Athersys (ATHX) traded up $0.06 on Monday, reaching $1.84. The company had a trading volume of 425,583 shares, compared to its average volume of 1,050,974. Athersys has a 1 year low of $1.02 and a 1 year high of $2.63.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Set $12.00 Target Price for Athersys, Inc. (ATHX)” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2017/11/16/zacks-analysts-set-12-00-target-price-for-athersys-inc-athx.html.

In other Athersys news, insider William Lehmann, Jr. sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of $2.38, for a total transaction of $35,700.00. Following the transaction, the insider now owns 527,380 shares in the company, valued at approximately $1,255,164.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.40% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in Athersys by 19.5% in the 1st quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock valued at $6,668,000 after buying an additional 637,322 shares in the last quarter. Mckinley Capital Management LLC Delaware purchased a new position in shares of Athersys during the 3rd quarter worth $1,093,000. Royal Bank of Canada raised its position in shares of Athersys by 7,334.0% in the 2nd quarter. Royal Bank of Canada now owns 380,846 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 375,723 shares during the period. Perkins Capital Management Inc. purchased a new position in shares of Athersys in the 3rd quarter worth $636,000. Finally, State Street Corp raised its position in shares of Athersys by 27.2% in the 2nd quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock worth $2,161,000 after buying an additional 305,944 shares during the period. Institutional investors and hedge funds own 19.33% of the company’s stock.

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Get a free copy of the Zacks research report on Athersys (ATHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply